HONEYWELL TEAMS UP WITH ASTRAZENECA TO DEVELOP NEXT-GENERATION RESPIRATORY INHALATORS THAT USE NEAR-ZERO GLOBAL WARMING POTENTIAL PROPELLANT

CHARLOTTE, NC, Feb. 22, 2022 /PRNewswire/ — Honeywell (Nasdaq: HON) today announced a commercial partnership with AstraZeneca (LON: AZN) to develop and bring to market next-generation respiratory inhalers that use near-zero global warming potential (GWP) propellants to treat asthma and chronic obstructive pulmonary disease (COPD).

As many as 384 million people suffer from COPD, a progressive respiratory disease, and 339 million children and adults suffer from asthma.1,2 Many of these patients are currently treated with metered-dose inhalers pressurized (pMDI) that can contribute to the footprint of respiratory care.

AstraZeneca, a global leader in the treatment of respiratory diseases, is working to integrate Honeywell’s Solstice® Air (HFO-1234ze cGMP) as a medical propellant, reducing pMDI greenhouse gas emissions by up to 99.9% compared to current inhaler propellants. Solstice Air is the only near-zero GWP non-flammable propellant available and in clinical development today for pMDIs.

A recently completed Phase I clinical trial of propellant HFO-1234ze in a pMDI containing budesonide, glycopyrronium and formoterol fumarate in healthy adults was positive, demonstrating a similar safety and tolerability profile and exposure systemic active ingredients compared to Breztri Aerosphere (budesonide/ glycopyrronium/ formoterol fumarate). AstraZeneca expects Breztri Aerosphere to be the first drug to transition to the next-generation pMDI platform, subject to regulatory approval.

Following these positive Phase I trial results, AstraZeneca will advance a commercial partnership with Honeywell to develop their triple combination therapy, Breztri Aerosphereusing Honeywell’s near-zero GWP thruster technology.

Pascal Soriot, Chairman and CEO of AstraZeneca, said: “We are making great strides in our ambition to be carbon zero in our global operations by the end of 2025 and carbon negative across our entire chain. value by 2030. Our collaboration with Honeywell demonstrates AstraZeneca’s commitment. to advance sustainable innovation in healthcare, with the goal of improving patient outcomes while reducing our environmental footprint.

“The work we are doing with AstraZeneca to develop a respiratory inhaler, with a new propellant with near-zero global warming potential, is extremely important both for the environment and for patients with respiratory problems,” said Darius. Adamczyk, chairman and CEO of Honeywell. “Our goal is to reduce carbon emissions from respiratory healthcare without restricting patient choice or risking improved health outcomes. This is just one example of how Honeywell is innovating to help our customers, like AstraZeneca, meet their environmental goals and stay focused on quality for their customers.”

Solstice Air is a breakthrough for pressurized metered dose inhalers (pMDIs). A non-flammable, low Global Warming Potential (GWP) alternative to hydrofluorocarbons, it does not deplete the ozone layer, is VOC-free (US EPA and CARB), with an ultra-low GWP close to 1. is the only new generation HFO. fuel-based propellant not currently subject to quota-based allocation under the recent 2020 American Innovation and Manufacturing (AIM).

Honeywell has invested a billion dollars in research, development and new capabilities for its Solstice technology, having anticipated the need for low-GWP solutions to combat climate change more than a decade ago. The product range, which helps customers reduce their greenhouse gas emissions and improve energy efficiency without sacrificing end-product performance, includes refrigerants for supermarkets, air conditioning for cars and trucks, blowing agents for insulation, propellants for personal and household care and solvents for cleaning. solutions.

Customers using Solstice technology have avoided the potential release of the equivalent of over 250 million metric tons of carbon dioxide into the atmosphere, equivalent to eliminating potential emissions from over 52 million cars for one year .

Honeywell is committed to achieving carbon neutrality in its operations and facilities by 2035. This commitment builds on the company’s track record of drastically reducing the greenhouse gas intensity of its operations. and facilities, as well as its decades of innovation to help its customers meet their expectations. environmental and social objectives. About half of Honeywell’s investment in new product introduction research and development is directed toward products that improve environmental and social outcomes for customers.

Honeywell (www.honeywell.com) is a Fortune 100 technology company that provides industry-specific solutions, including aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help planes, buildings, manufacturing plants, supply chains and workers become more connected to make our world smarter, safer and more sustainable. For more news and information about Honeywell, please visit www.honeywell.com/newsroom.

This release contains certain statements that may be deemed “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, that address the business, Events or developments that we or our management intend, anticipate, project, believe or anticipate will occur or may occur in the future are forward-looking statements. These statements are based on certain assumptions and assessments made by our management in light of their experience and perception of historical trends, current economic and industry conditions, expected future developments and other factors they deem appropriate. The forward-looking statements included in this release are also subject to a number of important risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors affecting our operations, markets, products , our services and our prices. These forward-looking statements are not guarantees of future performance, and actual results, developments and business decisions may differ from those contemplated by these forward-looking statements. We identify key risks and uncertainties affecting our performance in our Form 10-K and other filings with the Securities and Exchange Commission.

1. The Global Asthma Network. The World Asthma Report 2018. [Online]. Available at: http://www.globalasthmanetwork.org/. 2. World Health Organization. Top 10 causes of death.[OnlineAvailableat:[OnlineAvailableat:[EnligneDisponibleà:[OnlineAvailableat:https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death3. Adelloye D, et al. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015 ; 5 (2): 020415.

Quote Show original content to download multimedia:https://www.prnewswire.com/news-releases/honeywell-teams-with-astrazeneca-to-develop-next-generation-respiratory-inhalers-that-use-near-zero-global-warming-potential-proppellant- 301486896.html

SOURCEHoneywell